Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Prosonix Limited
Prosonix Limited
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Proposed acquisition of Aerocrine and Prosonix by Circassia Pharmaceuticals
Creating a world-class speciality pharmaceutical allergy and asthma business
Research & Development
Prosonix appoints Frank Condella as Non-executive Director
He brings more than 30 years of business experience to the position
Research & Development
Prosonix appoints a Chief Business Officer
To drive business development and commercial strategy
Research & Development
Prosonix receives £1.3m grant from the Biomedical Catalyst
To accelerate development of Multi-component particle (MCP) based combination respiratory medicines
Research & Development
Prosonix collaboration to speed up development of respiratory medicines
Prosonix and Imperial College London to accelerate development of engineered Multi-component Particles
Research & Development
Prosonix appoints chief medical officer
Oxford firm hires respiratory drug development expert Dr Geoff Down
Prosonix appoints first head of regulatory affairs
Rob Crocker joins Oxford, UK firm to take up the new role
Subscribe now